Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Is Biotech Back? This Analyst Sees 18% Upside Potential In This Bio Play

Published 08/08/2022, 16:55
Updated 08/08/2022, 17:40
© Reuters.  Is Biotech Back? This Analyst Sees 18% Upside Potential In This Bio Play
SRPT
-

Sarepta Therapeutics Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, announced Monday that it had signed licensing agreements with the Broad Institutes of both MIT and Harvard.

The move comes after the company made progress on one of its sponsored research agreements involving Duchenne muscular dystrophy and various other neuromuscular and cardiac indications.

Sarepta submitted a Biologics License Application (BLA), which seeks accelerated approval to treat muscular dystrophy.

Bullish news for the stock, and for analyst Gianni Di Poce, who said his price target is $125-$126 on Sarepta in his weekly “Benzinga Pro Insider Report.” Di Poce, an analyst at research firm The Mercator, highlighted that RNA technology has undergone ground-breaking innovation in recent years, and that Sarepta is well-positioned to benefit from this development in the healthcare industry. Not to mention, according to Di Poce, “the emerging strength being displayed by the biotech sector is impossible to ignore at this point.”

In contrast to the S&P 500, which has lost 12.74% year-to-date but gained 1.48% since the beginning of August — the Nasdaq Biotechnology index, while down 11.07% year-to-date, has gained more than 10% in the same time frame.

See Also: Is Funko Going To POP? Why This Analyst Predicts A 38% Move For The Stock

Sarepta booked $700 million in 2021, but lost $418.878 million overall.

“At a technical level, SRPT gapped up and broke out above a rounding bottom pattern,” Di Poce wrote. “A strong sign that upside momentum is set to accelerate.”

The company released its second-quarter earnings report on Aug. 2, which showed signs of growth. Quarterly sales came in at $233.49 million, beating the consensus estimates, while Sarepta posted losses of $1.18 per share, meeting the consensus estimates.

The company raised its 2022 sales guidance to $905-$920 million, up from a previously estimated $899.91 million.

Di Poce action plan: 18% return

“I am bullish on SRPT as long as the stock remains above $91.00-$92.00,” the analyst said. “Upside target $125.00-$126.00.”

Image courtesy of Sarepta Therapeutics

Latest Ratings for SRPT

DateFirmActionFromTo
Mar 2022 Morgan Stanley (NYSE:MS)MaintainsEqual-Weight
Mar 2022RBC CapitalMaintainsOutperform
Feb 2022Morgan StanleyMaintainsEqual-Weight
View More Analyst Ratings for SRPT

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.